- Click here for full review (subscribers only).
Abstract
- Reliable evidence supports the use
of thiazide diuretics (chlortalidone or
hydrochlorothiazide) as first-line treatment
for uncomplicated arterial hypertension.
- When patients fail to reach blood
pressure targets with well-conducted
treatment with thiazide diuretics, or
this treatment is poorly tolerated, what
are the best second-line options? To
answer this question, we reviewed the
available evidence, based on our standard
in-house methodology.
- We found no published trials specifically
designed to evaluate second-line
antihypertensive treatments in cardiovascular
prevention.There were no
available trials of dual- versus singleagent
therapy after failure of a thiazide
diuretic.
- When the blood pressure target is
not reached, inadequate drug efficacy
is only one of several possible causes.
Various other factors affecting blood
pressure should also be investigated.
- Dual-agent therapy carries an
increased risk of adverse effects and
drug interactions compared to
monotherapy.
- There is no consensus among clinical
practice guidelines on second-line
antihypertensive therapy.However, to
minimise the risk of adverse effects, it
is clearly better to select single-agent
therapy with a drug that has been
shown to prevent cardiovascular events
in first-line treatment of otherwise
healthy hypertensive patients.Possible
options include: angiotensin-converting-
enzyme inhibitors, angiotensin II
antagonists, calcium channel blockers
or betablockers. In patients over the
age of 60, betablockers seem less effective
than the other drugs in preventing